Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer
BACKGROUND AND OBJECTIVES: Since previous studies have indicated there are improvements in overall survival, the aim of this phase II clinical study was to evaluate docetaxel every three weeks plus prednisone as first-line chemotherapy for treatment of hormone-refractory metastatic prostate cancer (...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2010-07-01
|
| Series: | Hematology/Oncology and Stem Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387610500220 |